# IBEX (NCT06107738)

> Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06107738
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Barbara Ann Karmanos Cancer Institute
- Conditions: Multiple Myeloma
- Interventions: Iberdomide; Daratumumab/rHuPH20 Co-formulation
- Enrollment: 60
- Primary outcome: Rate of MRD (-) at 12 months

## Commentary we found

- X threads: 4
- YouTube: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ibex-nct06107738